Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 3, 2010, Pages 243-253

  Ito, Takashi ^a   Kato, Motohiro ^b   Chiba, Koji ^c   Okazaki, Osamu ^a   Sugiyam, Yuichi ^d  

^a DAIICHI SANKYO CO   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

CYP2D6; Drug development; Interindividual variability; Monte carlo simulation; Urinary metabolic ratio

Indexed keywords

CYTOCHROME P450 2D6; DEBRISOQUINE; DEXTROMETHORPHAN; DRUG METABOLITE; METOPROLOL; SPARTEINE; DRUG;

ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; HISTOGRAM; INDIVIDUALITY; KIDNEY METABOLISM; MATHEMATICAL COMPUTING; PHENOTYPIC VARIATION; POPULATION RESEARCH; STATISTICAL MODEL; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; MONTE CARLO METHOD; PHENOTYPE; PHYSIOLOGY; URINE;

CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; SPARTEINE; URINE;

EID: 77954285528     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.243     Document Type: Article

References (41)

1. Kato, M., Ito, T., Koue, T., Chiba, K. and Sugiyama, Y.: Virtual clinical trials (I): Prediction of interindividual difference in bioavailability. 21st Annual meeting of the Japanese Society for the Study of Xenobiotics, 237 (2006).
2. Bertz, R. J. and Granneman, G. R.: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet., 32: 210-258 (1997).
3. Zanger, U. M., Raimundo, S. and Eichelbaum, M.: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn. Schmiedebergs. Arch. Pharmacol., 369: 23-37 (2004).
4. Zhou, S. F.: Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet., 48: 689-723 (2009).
5. Yokota, H., Tamura, S., Furuya, H., Kimura, S., Watanabe, M., Kanazawa, I., Kondo, I. and Gonzalez, F. J.: Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics., 3: 256-263 (1993).
6. Dahl, M. L., Yue, Q. Y., Roh, H. K., Johansson, I., Sawe, J., Sjoqvist, F. and Bertilsson, L.: Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics, 5: 159-164 (1995).
7. Shen, H., He, M. M., Liu, H., Wrighton, S. A., Wang, L., Guo, B. and Li, C.: Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos., 35: 1292-1300 (2007).
8. Broly, F., Gaedigk, A., Heim, M., Eichelbaum, M., Morike, K. and Meyer, U. A.: Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol., 10: 545-558 (1991).
9. Dahl, M. L., Johansson, I., Palmertz, M. P., Ingelman-Sundberg, M. and Sjoqvist, F.: Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin. Pharmacol. Ther., 51: 12-17 (1992).
10. Cascorbi, I.: Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur. J. Clin. Invest., 33 Suppl 2: 17-22 (2003).
11. Evans, D. A., Mahgoub, A., Sloan, T. P., Idle, J. R. and Smith, R. L.: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet., 17: 102-105 (1980).
12. Eichelbaum, M. and Woolhouse, N. M.: Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur. J. Clin. Pharmacol., 28: 79-83 (1985).
13. Schmid, B., Bircher, J., Preisig, R. and Kupfer, A.: Polymorphic dextromethorphan metabolism: co-segregation of oxidative Odemethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther., 38: 618-624 (1985).
14. Dalen, P., Dahl, M. L., Eichelbaum, M., Bertilsson, L. and Wilkinson, G. R.: Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics, 9: 697-706 (1999).
15. Zanger, U. M., Fischer, J., Raimundo, S., Stuven, T., Evert, B. O., Schwab, M. and Eichelbaum, M.: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics, 11: 573-585 (2001).
16. Wennerholm, A., Johansson, I., Massele, A. Y., Lande, M., Alm, C., Aden-Abdi, Y., Dahl, M. L., Ingelman-Sundberg, M., Bertilsson, L. and Gustafsson, L. L.: Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics, 9: 707-714 (1999).
17. Bertilsson, L., Lou, Y. Q., Du, Y. L., Liu, Y., Kuang, T. Y., Liao, X. M., Wang, K. Y., Reviriego, J., Iselius, L. and Sjoqvist, F.: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther., 51: 388-397 (1992).
18. Jackson, P. R., Tucker, G. T., Lennard, M. S. and Woods, H. F.: Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br. J. Clin. Pharmacol., 22: 541-550 (1986).
19. Tucker, G. T., Jackson, P. R., Lennard, M. S. and Woods, H. F.: The detection of polymorphic drug oxidation-some theoretical and practical aspects. Prog. Clin. Biol. Res., 214: 413-424 (1986).
20. Granvil, C. P., Krausz, K. W., Gelboin, H. V., Idle, J. R. and Gonzalez, F. J.: 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J. Pharmacol. Exp. Ther., 301: 1025-1032 (2002).
21. Funck-Brentano, C., Boelle, P. Y., Verstuyft, C., Bornert, C., Becquemont, L. and Poirier, J. M.: Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur. J. Clin. Pharmacol., 61: 821-829 (2005).
22. Brosen, K., Otton, S. V. and Gram, L. F.: Sparteine oxidation polymorphism: a family study. Br. J. Clin. Pharmacol., 21: 661-667 (1986).
23. Daly, A. K., Armstrong, M., Monkman, S. C., Idle, M. E. and Idele, J. R.: Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics, 1: 33-41 (1991).
24. Mcginnity, D. F., Parker, A. J., Soars, M. and Riley, R. J.: Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab. Dispos., 28: 1327-1334 (2000).
25. Von Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Venkatakrishnan, K., Schmider, J., Harmatz, J. S. and Shader, R. I.: Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J. Pharm. Pharmacol., 50: 997-1004 (1998).
26. Eichelbaum, M., Reetz, K. P., Schmidt, E. K. and Zekorn, C.: The genetic polymorphism of sparteine metabolism. Xenobiotica, 16: 465-481 (1986).
27. Sloan, T. P., Lancaster, R., Shah, R. R., Idle, J. R. and Smith, R. L.: Genetically determined oxidation capacity and the disposition of debrisoquine. Br. J. Clin. Pharmacol., 15: 443-450 (1983).
28. Schadel, M., Wu, D., Otton, S. V., Kalow, W. and Sellers, E. M.: Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J. Clin. Psychopharmacol., 15: 263-269 (1995).
29. Bertilsson, L. and Dahl, M. L.: Polymorphic drug oxidation. CNS Drugs, 5: 200-223 (1996).
30. Griese, E. U., Zanger, U. M., Brudermanns, U., Gaedigk, A., Mikus, G., Morike, K., Stuven, T. and Eichelbaum, M.: Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics, 8: 15-26 (1998).
31. Sharma, A., Pibarot, P., Pilote, S., Dumesnil, J. G., Arsenault, M., Belanger, P. M., Meibohm, B. and Hamelin, B. A.: Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. J. Pharmacol. Exp. Ther., 313: 1172-1181 (2005).
32. McGourty, J. C., Silas, J. H., Lennard, M. S., Tucker, G. T. and Woods, H. F.: Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies. Br. J. Clin. Pharmacol., 20: 555-566 (1985).
33. Yeh, G. C., Tao, P. L., Ho, H. O., Lee, Y. J., Chen, J. Y. and Sheu, M. T.: Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. J. Biomed. Sci., 10: 552-564 (2003).
34. Frank, D., Jaehde, U. and Fuhr, U.: Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur. J. Clin. Pharmacol., 63: 321-333 (2007).
35. Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G. and Fuselli, S.: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics, 17: 93-101 (2007).
36. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423 (1994).
37. Yeo, K. R., Rostami-Hodjegan, A. and Tucker, G. T.: Proceedings of the British pharmacological society: Abundance of cytochrome P450 in human liver: a meta-analysis. Br. J. Clin. Pharmacol., 57: 687-688 (2003).
38. Evans, D. A., Harmer, D., Downham, D. Y., Whibley, E. J., Idle, J. R., Ritchie, J. and Smith, R. L.: The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J. Med. Genet., 20: 321-329 (1983).
39. Yu, A., Dong, H., Lang, D. and Haining, R. L.: Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab. Dispos., 29: 1362-1365 (2001).
40. Ito, K., Hallifax, D., Obach, R. S. and Houston, J. B.: Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab. Dispos., 33: 837-844 (2005).
41. Shimizu, H., Noguchi, H., Takashima, M., Higashio, T., Azuma, J. and Ueki, M.: The influence of food on the bioavailability of slow-release metoprolol tartrate 120 mg tablet in healthy volunteers and serum protein binding of metoprolol. Xenobio. Metab. Dispos., 6: 561-178 (1991).